Symptom burden of patients with moderate-to-severe atopic dermatitis

被引:10
|
作者
Egeberg, Alexander [1 ]
Anderson, Peter [2 ]
Piercy, James [3 ]
Massey, Lucy [4 ]
Cappelleri, Joseph C. [5 ]
Encinas, Gerardo A. [6 ]
Feeney, Claire [7 ]
Dibonaventura, Marco [8 ]
机构
[1] Univ Copenhagen, Bispebjerg Univ Hosp, Dept Dermatol, Nielsine Nielsens Vej 9, DK-2400 Copenhagen, Denmark
[2] Adelphi Mill, Adelphi Real World, Brand & Sci Commun, Macclesfield SK10 5JB, Cheshire, England
[3] Adelphi Mill, Hlth Econ & Outcomes Res, Adelphi Real World, Macclesfield SK10 5JB, Cheshire, England
[4] Adelphi Mill, Stat Anal, Adelphi Real World, Macclesfield SK10 5JB, Cheshire, England
[5] Pfizer Inc, Dept Stat, 445 Eastern Point Rd, Groton, CT 06340 USA
[6] Pfizer Inc, Emerging Markets, 3930 Braemar Pl, N Vancouver, BC V7N 4M8, Canada
[7] Pfizer Ltd, Global TA Med Affairs, Dorking Rd,Walton Hill, Tadworth KT20 7NS, Surrey, England
[8] Pfizer Inc, Hlth Econ & Outcomes Res, 235 East 42nd St, New York, NY 10017 USA
关键词
atopic dermatitis; burden; health-related quality-of-life; HEALTH;
D O I
10.1684/ejd.2021.4166
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with intense and persistent pruritus. Objectives: To examine associations between AD symptoms and health-related quality of life (HRQoL) in adults (aged >= 18 years) with moderate-to-severe AD. Materials & Methods: Patient chart and survey data from physicians within Europe were derived from the Adelphi AD Disease Specific Programme (Q3 2019-Q2 2020). HRQoL measures included Euro-Qol 5-dimension, 3-level, questionnaire; Dermatology Life Quality Index; and Work Productivity and Activity Impairment-Atopic Dermatitis questionnaire. Data were evaluated using descriptive statistics and generalized linear models. Results: Of 631 patients, 90.1%, 49.3%, 18.5% and 17.7% reported pruritus, sleep disruption, anxiety and depression, respectively. Adjusted analyses indicated an increased frequency of symptoms associated with worse HRQoL and greater work/activity impairments, particularly for patients with pruritus and sleep disruption. Conclusion: Reductions in symptom frequency may have important implications for improving the overall health of patients with moderate-to-severe AD.
引用
收藏
页码:752 / 758
页数:7
相关论文
共 50 条
  • [21] Treatment satisfaction in patients receiving dupilumab for moderate-to-severe atopic dermatitis
    Lans, A.
    Van der Schaft, J.
    Bakker, D.
    Ariens, L.
    Thijs, J. H.
    De Bruin-Weller, M. S.
    Balak, D. M. W.
    ALLERGY, 2019, 74 : 82 - 82
  • [22] Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis
    Murase, Jenny E.
    Chovatiya, Raj
    Strowd, Lindsay
    Thyssen, Jacob P.
    Bangert, Christine
    Atwater, Amber Reck
    Gallo, Gaia
    Bardolet, Laia
    Yang, Fan
    Zhong, Jinglin
    Staumont-Salle, Delphine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [23] COMPARING DERMATOLOGY LIFE QUALITY INDEX (DLQI) BETWEEN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS AND MODERATE-TO-SEVERE PSORIASIS PATIENTS
    Kim, Yeong Ho
    Yoo, Seung Ah
    Han, Ju Hee
    Lee, Ji Hae
    Bang, Chul Hwan
    Lee, Young Bok
    Kim, Jung Eun
    Park, Hyun Jung
    Park, Chul Jong
    Lee, Ji Hyun
    Cho, Sang Hyun
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 20 - 20
  • [24] Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis
    Ameen, Mahreen
    Alhusaye, Raed
    Brandi, Henrik
    Bogelund, Mette
    Jensen, Henrik H.
    Reitzel, Signe B.
    Thyssen, Jacob P.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [25] Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis
    Nezamololama, Novin
    Crowley, Erika L.
    Gooderham, Melinda J.
    Papp, Kim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 911 - 917
  • [26] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Hamilton, Jennifer D.
    Graham, Neil M.
    Bieber, Thomas
    Rocklin, Ross
    Ming, Jeffrey E.
    Ren, Haobo
    Kao, Richard
    Simpson, Eric
    Ardeleanu, Marius
    Weinstein, Steven P.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    Suarez-Farinas, Mayte
    Hager, Melissa D.
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
  • [27] Validation of the pruritus and symptoms assessment for atopic dermatitis in adults with moderate-to-severe atopic dermatitis
    Lebwohl, M. G.
    Simpson, E. L.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Gooderham, M. J.
    Wollenberg, A.
    Hall, R.
    Gater, A.
    Wells, J. R.
    Papacharalambous, J.
    Hsu, M. A.
    Tallman, A. M.
    Peeva, E.
    Zhang, W.
    Chen, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E44
  • [28] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Okragly, Angela
    Sun, Zhe
    Mena, Laura Rebeca
    Hahn, Nathan
    Nickoloff, Brian J.
    Siu, Kimberly
    Gallo, Gaia
    Wolf, Eric
    Eyerich, Kilian
    Aparici, Monica
    Benschop, Robert J.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II4 - II5
  • [29] Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients
    Dal Bello, Giacomo
    Maurelli, Martina
    Schena, Donatella
    Girolomoni, Giampiero
    Gisondi, Paolo
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [30] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L. R.
    Hahn, N.
    Nickoloff, B. J.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364